NEW YORK, NY--(Marketwire - Sep 12, 2011) - IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) ("IntelliCell" or the "Company"), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, announced today that it will be presenting at the Rodman & Renshaw Annual Global Investment Summit in New York on September 11th through 13th.
The Company's CEO and Chairman, Dr. Steven Victor, will be presenting at the conference in an effort to inform the investment community of IntelliCell's very promising proprietary process of separating stromal vascular fraction, containing a high content of stem cells, from adipose tissue.
The use of autologous adipose (fat) stem cells for a growing variety of indications is a new and exciting frontier in medicine. In the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the US FDA published its laws on autologous stem cells the field has expanded rapidly. Currently, numerous doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments.
"I'm very pleased to share our progress with the Rodman & Renshaw investment community. They are a trusted ally to many in the financial landscape and we feel we have some exciting advancements to share with them," said IntelliCell BioSciences CEO and Chairman, Steven Victor.
IntelliCell's adipose stem cell processing technique takes approximately 30 minutes and the stem cells can be returned to the doctor in the same day. Autologous adipose stem cells are on the cutting edge of medicine and IntelliCell is excited to be one of the companies to participate in this field.
IntelliCell has developed an in-house technology where it can easily process stromal vascular cells containing a high concentration of adipose stem cells with excellent viability. At present, management believes it is the only company that does not use enzymes in processing adipose tissue and actually counts and checks the adipose stem cells they manufacture.
About IntelliCell BioSciences, Inc.
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on setting up tissue processing centers throughout the United States with managing partners. The centers will receive and employ the IntelliCell™ process to the adipose stromal vascular fraction harvested by physicians in their own offices, and then return the IntelliCells™ to the physicians the same day labeled "autologous homologous." IntelliCell has already established processing centers in Baton Rouge, New York City, Philadelphia, Dallas/Ft. Worth, Denver, Houston, New Orleans, Orlando, and West Palm Beach. In the future, IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit http://www.intellicellbiosciences.com or call 212 249 3050.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.